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EGFR inhibition has emerged to be an important strategy in the treatment of non-small cell lung cancer (NSCLC).
Small molecule tyrosine kinase inhibitors (TKIs) and mono-clonal antibodies (mAbs) to the EGFR have been tested
in multiple large randomized phase III studies alone or combined with chemotherapy, as well as small phase I-II
studies which investigated their efficacy as radiosensitizers when combined with radiotherapy. In this review, we
described the current clinical outcome after treatment with EGFR TKIs and mAbs alone or combined with
chemotherapy in advanced stage NSCLC, as well as the early findings in feasibility/phase I or II studies regarding to
whether EGFR TKI or mAb can be safely and effectively combined with radiotherapy in the treatment of locally
advanced NSCLC. Furthermore, we explore the potential predictive biomarkers for response to EGFR TKIs or mAbs
in NSCLC patients based on the findings in the current clinical trials; the mechanisms of resistance to EGFR
inhibition; and the strategies of augmenting the antitumor activity of the EGFR inhibitors alone or when combined
with chemotherapy or radiotherapy.
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The epidermal growth factor receptor (EGFR), a 170 kD
transmembrane protein consisted of a N-terminus extra-
cellular ligand-binding site, a hydrophobic transmembrane
domain, and a C-terminus intracellular region with tyro-
sine kinase activity, is the first of the ErbB family of recep-
tor tyrosine kinases (RTKs) [1,2]. The other members
include ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4
(HER4). These receptors trigger downstream signaling
pathways which lead to multilayered, complex interactions
resulting in combinatorial responses. Disruption of these
pathways was found to cause malignant transformation
[1]. The EGFR is activated through ligand-induced homo
or heterodimerization of the receptor with other receptors
of the ErbB family under physiologic conditions, but can
also be activated due to receptor over-expression, increase
of EGFR gene copy number, and activating mutations [3].
EGFR activation has been shown to play a key role in
tumor cell proliferation, apoptosis, tumor-induced angio-
genesis, metastasis, and DNA damage repair after* Correspondence: achiaz2010@gmail.com
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reproduction in any medium, provided the orcytotoxic insults [1,4]. This makes it an attractive target in
cancer therapy; and its inhibition a strategy for augmenta-
tion of the efficacy of chemotherapy and radiotherapy.
Since the initial discovery of the EGFR in 1962, a class of
antibodies blocking the EGFR’s extra-cellular ligand bind-
ing site to prevent receptor activation, and to down-
regulate EGFR expression at the cell surface through anti-
body mediated receptor dimerization; and low molecular
weight tyrosine kinase inhibitors, which competes with
ATP to bind to the intra-cellular tyrosine kinase portion
of the receptor to abrogate the receptor’s catalytic activity
to activate downstream signaling pathways, have been
developed [1,4-6]. Among them, reversible small molecule
(SM) tyrosine kinase inhibitors (TKIs), Gefitinib and Erlo-
tinib, and the mono-clonal antibody (mAb) against EGFR,
Cetuximab, have been the most thoroughly investigated.
Both Cetuximab and the SM TKIs have been shown to
have significant antitumor activity in various EGFR over-
expressing cancers, and to enhance the potency of chemo-
therapy or radiotherapy in various pre-clinical and early
phase I or II clinical studies [1,6-8].
As the leading cause of cancer mortality worldwide,
50-80% of non-small cell lung cancer (NSCLC) is asso-
ciated with EGFR overexpression; with 65% of them also. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[9-11]. Given the high percentage of NSCLC being diag-
nosed in the advanced stage with a poor survival out-
come, EGFR inhibition alone or combined with other
approaches in the treatment of NSCLC become a very
attractive strategy which has been validated in pre-
clinical and preliminary clinical trials [12-14]. This led to
further phase III randomized studies assessing the effi-
cacy of combining a SM TKI or Cetuximab with chemo-
therapy as the first line treatment of stage IIIB-IV
NSCLC; and some feasibility/phase I & II studies on
their combination with radiotherapy, or chemo-radiation
in the treatment of local-regional disease. In the follow-
ing sections, we will describe the current clinical evi-
dence on the utility of TKIs and Cetuximab with
chemotherapy in the treatment of advanced stage
NSCLC, their role in the treatment of loco-regionally
confined NSCLC, such as radiosensitization; patient se-
lection, and potential strategies of further enhancing
their efficacy.
EGFR TKIs alone or combined with chemotherapy
as first line treatment
Numerous phase III studies on TKI alone or combined
with chemotherapy as first line treatment for stage IIIB-
IV NSCLC have been conducted since Gefitinib has
been approved by the Food and Drug Administration
(FDA) in 2003, and Erlotinib has been approved by the
FDA in 2004 for chemotherapy-resistant stage IIIB-IV
NSCLC [14-23]. In 2004, two large phase 3 randomized
studies evaluating the benefit of adding Gefinitib to
chemotherapy as first line treatment for stage IIIB-IV
NSCLC have been reported [15,16]. In INTACT 1, 1093
patients were randomized to placebo, Gefitinib 250 mg/
day, and Gefitinib 500 mg/day after up to six cycles of
Cisplatin and Gemcitabine. No differences in objective
response rate (ORR), progression free survival (PFS), or
overall survival (OS) was found between the 3 arms after
median follow up of 15.9 months. The treatment was
very well tolerated with no difference in the incidence of
interstitial lung disease (ILD) reported and an overall in-
cidence of ILD <1% [15]. In a parallel study, INTACT 2,
similar findings were obtained after randomizing 1037
patients to placebo, Gefitinib 250 mg/day, and Gefitinib
500 mg/day after up to 6 cycles of Carboplatin and
Paclitaxel in as first line treatment for stage IIIB/IV
patients [16]. The addition of Gefitinib was again very
well tolerated with only 0.9%, 2.1%, and 1.5% of ILD
found in the three arms, respectively. In the subsequent
year, a randomized trial (TRIBUTE) comparing first line
Carboplatin and Paclitaxel up to 6 cycles and the same
regimen combined with concurrent and maintenance
Erlotinib (150 mg/day) in 1079 patients [17]. In this
study, no difference in ORR, PFS, or OS was foundbetween the two arms. However, a survival benefit from
maintenance Erlotinib was found in patients who lived
longer than 4 months, which suggested a benefit from
maintenance therapy with Erlotinib. There were 5 cases
of ILD-like in the Erlotinib arm (1.0%) and 1 on the
chemotherapy arm (0.2%). All cases were fatal. Despite
the overall negative findings in this study, never smo-
kers, who tend to be younger, female, and have adeno-
carcinomas when compared with prior/current smokers,
were found to have a median survival of 22.5 months
with Erlotinib treatment and only 10.1 months when
treated with placebo.
Despite the disappointment with the INTACT and
TRIBUT studies, the importance of selecting patients
who will respond to TKIs has been recognized, which is
suggested by the prolonged survival observed in never
smokers [16,17]. This concept is also supported by the
findings of in-frame deletions in exon 19 and missense
mutations in exon 21 of the EGFR gene which lead to
increased signaling through the EGFR pathway, and
increased drug affinity at the EGFR’s intra-cellular tyro-
sine kinase ATP-binding site [24,25]. Furthermore, the
above mentioned EGFR mutations are more often found
in never-smokers as well [17].
To further classify the patients who will respond to
EGFR TKIs, a phase III randomized study (IPASS) com-
paring upfront Geftinib and Carboplatin/Paclitaxel in
stage IIIB-IV patients with the following characteristics
has been conducted in East Asia: never or former light
smokers with a diagnosis of adenocarcinoma [18]. A
total of 1217 patients were randomized in this study.
After a median follow up of 5.6 months, a superior 1 year
PFS with Gefitinib was found (24.9% vs. 6.7%, p <0.001).
Better ORR associated with Gefitinib was also reported
(43% vs. 32.2%, p <0.001). Among 437 patients whose
EGFR mutation data can be evaluated, 261 had EGFR
mutations identified. Out of these 261 patients, 53.6%
had exon 19 deletions, and 42.5% had a missense muta-
tion at exon 21. A predictor of TKI resistance [26,27], a
mutation at exon 20 (T790M) was also identified in 4.2%
of these patients. Among patients who harbored activat-
ing EGFR mutations on exon 19 and 21, a noticeably
increased ORR in patients who received Gefitinib was
found when compared with those who received chemo-
therapy (71.2% vs. 47.3%, p <0.001). The opposite was
found in patients without EGFR mutations (1.1% vs.
23.5%, p <0.001). No significant difference in toxicity
profile between the two treatment arms was found. This
study established that EGFR mutation, such as those on
exon 19 and 21, can be used as a predictive marker for
response to EGFR TKIs, which may be more effective
than chemotherapy in patients with these mutations. Its
findings were further validated in several other phase 3
randomized studies [19-22]. All these studies included
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21 only. All four studies confirmed the superior response
and PFS associated with an EGFR TKI over chemother-
apy in patients with activating EGFR mutations. The
details of these studies along with the studies described
above are shown in Table 1. One more recent report of
a trial (TORCH) comparing first line Erlotinib and Cis-
platin/Gemcitabine (CG) followed by either CG or Erlo-
tinib in unselected patients with stage IIIB-IV patients
has demonstrated negative outcomes associated with
Erlotinib after a median follow up of 24.3 months [23].
Thus, further validating the need to select patients basedTable 1 Phase III studies investigating the efficacy of EGFR in
stage IIIB-IV NSCLC
Study Stage Study arms # Pts
TKI
INTACT 1 [15] IIIB-IV Cisplatin + Gemcitabine
(CG) vs. CG + Gefitinib




INTACT 2 [16] III-IV Carboplatin + Paclitaxel
(CP) vs. CP + Gefitinib




TRIBUTE [17] IIIB-IV Carboplatin + Paclitaxel






































IIIB-IV Erlotinib vs. Platinum
based chemotherapy
86 vs. 87
TORCH [23] IIIB-IV Erlotinib vs. Cisplatin/
Gemcitabine as 1st line
treatment, and the




FLEX [33] IIIB-IV Cisplatin + Vinorelbine
(CV) vs. CV + Cetuximab
568 vs. 5
BMS099 [34] IIIB-IV Carboplatin + Taxane
(CT) vs. CT + Cetuximab
338 vs. 3
Abbreviations: ORR: objective response rate; PFS: progression free survival; OS: overaon specific EGFR mutations in NSCLC patients that are
associated with drug sensitivity to EGFR TKIs.
EGFR TKIs as 2nd line or maintenance therapy
While effective only in EGFR mutation positive patients
as first line treatment, both Gefitinib and Erlotinib have
been shown to achieve similar ORR, PFS, and OS when
compared with 2nd line chemotherapy in randomized
phase 3 studies [28,29]. EGFR FISH-negative tumors
were found to have a higher risk of disease progression
after Erlotinib in one study [29]. When compared with
placebo as maintenance therapy, Erlotinib treatment ledhibition alone or as part of the 1st line treatment for
ORR Median PFS Median OS
65 47.20% vs.
51.20% vs.
50.30%, p = ns
6.0 mo vs. 5.8 mo vs.
5.5 mo, p = 0.7633
10.9 mo vs. 9.9 mo vs.
9.9 mo, p = 0.4560
45 28.70% vs.
30.40% vs.
30.00%, p = ns
5.0 mo vs. 5.3 mo vs.
4.6 mo, p = 0.0562
9.9 mo vs. 9.8 mo vs.




4.9 mo vs. 5.1 mo,
p = 0.36





6.7% vs. 24.9% at
1 year, p <0.001




9.2 mo vs. 6.3 mo,
p <0.0001
30.9 mo vs. not
reached, p = 0.211
83% vs. 36%,
p <0.0001




10.8 mo vs. 5.4 mo,
p <0.001




9.7 mo vs. 5.2 mo,
p <0.0001








6.4 mo vs. 8.9 mo 8.7 mo vs. 11.6 mo
57 29% vs. 35%,
p = 0.010
4.8 mo vs. 4.8 mo,
p = 0.39





4.24 mo vs. 4.40 mo,
p = 0.2358
8.38 mo vs. 9.69 mo,
p = 0.169
ll survival.
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correlated with PFS [30]. In addition, EGFR mutation s
were associated a large improvement in PFS with the
addition of Erlotinib as maintenance therapy.
Cetuximab combined chemotherapy as first line
treatment
While a large amount of clinical evidence on how to
most effectively incorporate EGFR TKIs into the man-
agement of advanced NSCLC has been generated, the
clinical experience with mono-clonal antibodies in
advanced NSCLC is just emerging in recent years.
Cetuximab as a single agent generated minimal response
in advanced NSCLC [31]. However, its addition to first
line Cisplatin and Vinorelbine was shown to increase
tumor response in stage IIIB-IV NSCLC when compared
with the same chemotherapy alone in a phase II study
[32]. Two randomized phase III studies on the combin-
ation of Cetuximab with chemotherapy as first line treat-
ment have been reported subsequently [33,34]. In the
FLEX study, which randomized 1125 patients with stage
IIIB-IV NSCLC to Cetuximab delivered concurrently
with up to 6 cycles of Cisplatin and Vinorelbine and
until disease progression and the same chemotherapy
alone, the addition of Cetuximab led to significantly
increased ORR (35% vs. 29%, p = 0.010) and median sur-
vival (11.3 vs. 10.1 months, p = 0.044). Only 10% of the
patients experienced an acne-like rash on the Cetuximab
arm, and no >grade 3 acne-like rash was observed in this
study. The superior response associated with the
addition of Cetuximab to first line chemotherapy was
confirmed in another phase III randomized study (BMS
099) randomizing 676 patients to Carboplatin, plus a
taxane or Caboplatin-based chemotherapy combined
with Cetuximab, which is given till disease progression.
However, no survival benefit was demonstrated in that
study (Table 1). Only 10.5% grade 3 or 4 acne-like rash
was observed in this study.
Patient selection for EGFR TKIs or mAb in NSCLC:
the current evidence
Given the studies summarized above, it is clear that pa-
tient selection for EGFR TKI or mAb is essential as they
are only effective in a group of patients with certain bio-
logical traits. The association between EGFR mutations
and the efficacy of SM TKIs in phase 3 randomized
studies is direct evidence for this. As a result, predictive
biomarkers for efficacy of TKI or mAb treatment have
been sought in patients from various phase II/III and
prospective studies (Table 2). Among studies of a TKI
alone as 1st, 2nd, 3rd line treatment or maintenance ther-
apy, EGFR mutation was identified most frequently and
consistently as a predictor of tumor response, and sur-
vival outcome [35-40]. However, KRAS mutation, pAKTand HER-2 expression were also found to be possible
predictive biomarkers for survival outcome following
TKI treatment in selected studies [36-38]. When used in
combination with chemotherapy, EGFR mutation and
KRAS mutation and EGFR gene copy number are identi-
fied to be potential predictive biomarkers for TKI effi-
cacy [41,42]. It is also found that the EGFR gene copy
number predictive value depended on the EGFR muta-
tion status in the IPASS trial (Table 2).
Among phase II-III studies evaluating the efficacy of
Cetuximab, only the EGFR gene copy number and EGFR
mutation were found to be potential biomarkers for this
mAb’s efficacy (Table 2). Among the two large phase 3
randomized studies (BMS099 & FLEX trials), the EGFR
mutation was the only biomarker found to be predictive
of superior survival after either chemotherapy combined
with Cetuximab or chemotherapy alone in the FLEX
trial [44,45].
Based on the evidence generated from the studies
described thus far, the EGFR mutation status appear to
be the most consistently found predictive biomarker for
EGFR TKI or mAb efficacy in advanced NSCLC while
other potential markers, such as KRAS mutation and
EGFR gene copy number, need to be further evaluated
in larger cohort of patients in the future.
Potential role of EGFR TKI and mAb as
radiosensitizers
The EGFR has been known to play a key role in the acti-
vation of DNA repair and anti-apoptotic proteins, as
well as tumor cell repopulation after irradiation [8,46].
Upon irradiation, increased levels of EGFR auto-
phosphorylation has been observed, leading to the acti-
vation of the EGFR and its downstream signaling path-
ways [8]. Furthermore, its expression has been shown to
be correlated with radio-resistance and poor outcome
after radiotherapy in pre-clinical and clinical studies
[8,47]. Thus, adding an EGFR TKI or mAb to inhibit
EGFR activation induced by irradiation become a very
sound strategy in enhancing the radiocurability of EGFR
over-expressing cancers. This has been successfully vali-
dated in the treatment of locally advanced squamous cell
carcinoma of the head and neck. In a randomized phase
3 study comparing concurrent Cetuximab plus radio-
therapy and radiotherapy alone, a 9.2% 5 year overall
survival benefit (45.6% vs. 36.4%, p <0.05) was observed
with the addition of cetuximab [48]. As an EGFR over-
expression cancer, locally advanced NSCLC has been
treated with concurrent chemo-radiation with a 5-year
survival of approximately 15%, and 5 year loco-regional
control of approximately 70% based on major rando-
mized studies [49]. Despite the poor outcome observed,
concurrent chemoradiation is often associated with sig-
nificant toxicity, which prevents further radiation dose
Table 2 Predictive biomarkers in the major clinical trials
Study Study arms Predictive biomarkers
TKI
INTEREST [35] Gefitinib vs. Docetaxel in previous treated
patients
EGFR mutation predicted for longer PFS and higher ORR (p
<0.05) and high EGFR copy number predicted for higher ORR (p
<0.05) with Gefinitib vs. Docetaxel. KRAS mutation was not
predictive for response or survival.
SATURN [36] Maintenance Erlotinib vs. observation after
1st line chemotherapy
EGFR IHC, EGFR FISH, KRAS mutation and EGFR CA-SSR1 repeat
length status did not predict for drug response. EGFR mutation
predicted for PFS, and OS benefit after Erlotinib treatment KRAS
mutation predicted for poor PFS.
Italian Phase II study [37] EGFR-TKI as 2nd line treatment pAKT and HER-2 expression are the only independent predictors
of PFS and OS
ERMETIC [38] EGFR TKI as 1st, 2nd, or 3rd line treatment Median PFS: EGFR mutant 8.4 mo, EGFR wild type 2.3 mo, KRAS
mutant 1.9 mo, p = 0.001. Median OS: EGFR mutant 14.4 mo,
EGFR wild type 5.3 mo, KRAS mutant 4.1 mo, p = 0.004.
PUMC prospective study [39] Gefitinib after failing 1st line chemotherapy EGFR mutation is the only independent predictor of tumor
response.
IDEAL & INTACT trials [40] IDEAL trials: phase II studies on Gefitinib as
2nd line treatment; INTACT trials: phase III
studies investigating the benefit of adding
Gefitinib to chemotherapy as 1st line
treatment
EGFR mutation predicted for increased response to Gefitinib in
IDEAL trials, but not in the INTACT trials. KRAS mutation, PTEN
mutation or expression and p53 expression not associated with
clinical response to Gefitinib in the IDEAL trials.
TRIBUTE [41] Carboplatin + Taxol (CT) vs. CT + Erlotinib;
followed by Erlotinib maintenance
EGFR mutations (13%) in EGFR exons 18 through 21 were
predictive of OS overall; and superior response to CT + Erlotinib
(p <0.01). KRAS mutations (21%) at KRAS exon 2 was associated
with decreased TTP and OS in the CT + Erlotinib arm.
IPASS (Fukuoka JCO 11) [42]
Non-smokers or former light
smokers with adenocarcinoma
Carboplatin + Taxol vs. Gefitinib High EGFR gene copy number was associated with increased
PFS and ORR after Gefitinib vs. Carbo/Taxol. However, it
predicted for poorer PFS in the absence of EGFR mutation. EGFR
mutation at Exon 19 and 21 predicted for superior PFS and ORR
after Gefitinib.
Cetuximab
SWOG 0342 [43] Carbo/Taxol + Cetuximab vs. Carbo/Taxol;
Both followed by Cetuximab for 1 year
Increased EGFR gene copy numbers is associated with superior
PFS and OS (p <0.05)
BMS099 [44] Carboplatin + Taxane (CT) vs. CT +
Cetuximab
EGFR FISH, EGFR IHC, KRAS mutations and EGFR mutations did
not predict for ORR, PFS, or OS benefit with the addition of
Cetuximab
FLEX [45] Cisplatin + Vinorelbine (CV) vs. CV +
Cetuximab
KRAS (19%), EGFR FISH + (37%), PTEN negativity (35%) were of no
predictive value. EGFR mutation (15%) predicted for improved
OS in both arms (p <0.05).
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with radiotherapy or chemoradiation can potentially be a
more effective strategy in the treatment of locally
advanced NSCLC.
In pre-clinical studies of NSCLC, radiosensitizing
effects of both EGFR TKIs and mAbs have been
reported [13,50-54]. This has led to a series of studies
combining TKIs and mAbs to the EGFR with radiother-
apy or chemoradiation. Combining a TKI with radiother-
apy or chemoradiation has been shown to be feasible in
several studies [55-63]. As shown in Table 3, median
survival of >20 months was achieved in several studies
[58,59,62,63]. As shown by Wang et al., a concurrent
TKI and radiotherapy to 70 Gy in stage III-IV patients
achieved a median survival of 21.8 months, which is at
least comparable to what has been reported afterconcurrent chemoradiation [58,64,65]. However, the
addition of chemotherapy to TKI and radiotherapy may
possibly increase the risk of fatal pneumonitis and
hematologic toxicities [57,59]. Furthermore, the use of
concurrent chemotherapy, radiotherapy and EGFR TKI
may not be better than combined TKI and radiotherapy
[61]. Disappointing survival outcome is again demon-
strated in another phase II study investigating induction
chemotherapy followed by concurrent chemotherapy,
TKI, and radiotherapy to 74 Gy [60]. This implies the
potential risk of increased toxicity when combining
chemotherapy, EGFR TKI and radiotherapy; and also the
importance of drug treatment sequencing for chemo-
therapy and TKI. As shown in a different study, which
delivers 1 dose of chemotherapy followed by subsequent
doses of TKI each week with radiotherapy, median
Table 3 EGFR tyrosine kinase inhibitors or mono-clonal antibodies combined with radiotherapy
Study Study scheme Stage #Pts RT Dose (Gy) ORR Median PFS Median OS
TKI
Okamoto et al [55] Gefitinib x 14 days, then given
concurrently with RT
III 9 60 Gy 4 pts who
completed
with PR
2 pts with EGFR
mutations lived
>5 yrs.
Choong et al [56] Erlotinib + Cisplatin + Etoposide +
RT then docetaxel x 3 cycles vs.
Carboplatin + Paclitaxel , then
Erlotinib + Carboplatin + Paclitaxel
+ RT
III 17 vs. 17 66 Gy 65% vs. 59%,
p = ns
13% vs. 15% at
3 yrs, p = 0.9168
11 mo vs. 15 mo,
p = 0.8979
Rothschild et al [57] Erlotinib + RT or Erlotinib +
Cisplatin + RT
III 14 63 Gy 21.4% 6.0 mo 12.7 mo
Wang et al [58] Gefitinib or Erlotinib + RT III/IV 26 70 Gy 96% 10.2 mo 21.8 mo
Center et al [59] Gefitinib + Docetaxel + RT III 16 70 Gy 7.1 mo 21.0 mo
Stinchcombe et al
[60]
Carboplatin + Irinotecan + Taxol
followed by Carboplatin/Taxol +
Gefitinib + RT
III 23 74 Gy 24% 9 mo 16 mo
Ready et al [61] Carboplatin/Taxol x 2 cycles ±
Gefitinib then Gefinitib + RT vs.
Carboplatin/Taxol + Gefitinib + RT;
both groups are given Gefitinib
after RT if w/o severe radiation
toxicity.
III 21 vs. 39 66 Gy 52.40% vs.
81.60%,
p = 0.034
13.4 mo vs. 9.2
mo
19.0 mo vs. 13.0
mo
Chang et al [62] Upfront TKI, followed by TKI +
multitarget IMRT with helical
tomotherapy
IIIB-IV 25 40-50 Gy in
16–20 daily
fractions.
84% 16 mo Not reached, 3 yr
OS 62.5%
Komaki et al [63] Carboplatin + Paclitaxel on
Monday, followed by Erlotinib for
the rest of the week combined
with RT; Consolidative
Carboplatin + Paclitaxel x 2 cycles
were then given
III 46 63 Gy/ 35
daily fractions
80% 14.5 mo 34.1 mo
Cetuximab or Nimotuzumab
Hughes et al [66] Platinum based chemotherapy
followed by Cetuximab + RT
III-IV 12 64 Gy 70%
Choi et al [67] Weekly Nimotuzumab + RT, then
q2 weeks till progression
IIB-IV 15 30 or 36 Gy
in 3 Gy
fractions
46.70% 5.4 mo 9.8 mo
Bebb et al [68] Weekly Nimotuzumab + RT, then
q2 weeks till progression
III-IV 18 30 or 36 Gy
in 3 Gy
fractions
66% 4 mo 15 mo
Govindan et al [69] Carboplatin + Pemetrexed + RT vs.
Carboplatin + Pemetrexed +
Cetuximab + RT
III 48 vs. 53 70 Gy 77% vs. 72%,
p = ns
12.6 mo vs. 12.3
mo, p = ns
21.2 mo vs. 25.2
mo, p = ns
Jensen et al [70] Cetuximab + RT followed by
maintemance Cetuximab
III 30 66 Gy 8.5 mo 19.6 mo
Hallqvist et al [71] Cisplatin + Docetaxel followed by
Cetuximab + RT
III 75 68 Gy 23.5% 17 mo
Blumenschein et al
[72]
Carboplatin + Taxol + Cetuximab
+ RT followed Carboplatin + Taxol
+ Cetuximab
III 87 63 Gy 62% 12 mo 22.7 mo
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ment was delivered in this fashion [63]. Due to the size
of the studies, predictive biomarkers have not been con-
sistently identified. However, long term survival and ex-
cellent overall survival have been reported in patients
who harbor EGFR mutations (deletion on exon 19) andwho responded to upfront TKI [55,62]. Again, suggest-
ing the importance of patient selection in the application
of TKI’s as radiosensitizers.
A limited number of studies investigating the radio-
sensitizing effects of a mAb have been reported as well
(Table 3). Among them, several have translated into
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after concurrent chemoradiation [64,65,69-72]. The
addition of Cetuximab or Nimotuzumab to radiotherapy
or chemoradiation appear to be well tolerated with
>grade 3 pneumonitis reported only in cases which had
excessive amount of radiation dose to the normal lung
tissue [66-72]. The results from RTOG 0617, a con-
firmatory intergroup trial evaluating the addition of
cetuximab to chemoradiation in stage III NSCLC are
eagerly anticipated.
Future directions
The findings from large phase III randomized studies
demonstrated that patient selection is essential in the
application of EGFR TKI in the treatment of stage IIIB-
IV NSCLC. Patients who harbor a activating EGFR mu-
tation usually responds very well to treatments including
EGFR TKI or mAb alone or combined with chemother-
apy and/or radiotherapy [35,36,38-42,45,55]. This further
confirmed previous findings in phase II studies, which
demonstrated higher response rates to EGFR TKIs in
patients with activating EGFR mutations than that found
after platinum-based chemotherapy, but very poor re-
sponse in patients with only wild type EGFR expression
[73]. The response associated with EGFR mutations is
thought to be due mainly to an “addictive” dependence
of tumor cells on the EGFR signaling pathway for sur-
vival [73]. However, response to the EGFR TKIs may be
short lived due possibly to a secondary mutation in the
EGFR (T790M), or increased signaling through pathways
downstream to the EGFR without its activation
[26,27,74]. T790M may increase the GTP affinity in the
tyrosine kinase domain of the EGFR, or hindrance to
TKI binding to the tyrosine kinase domain [75,76]. As
shown by Su et al., T790M appears to be more prevalent
in patients who has not had any TKI treatment (25.2% -
31.5%), and it becomes even more prevalent after TKI
treatment (83.3%) [76]. This finding suggests that TKI
treatment selects for NSCLC cells with T790M mutation,
and new strategy needs to be developed to overcome
T790M related resistance. Further shown by Su et al.,
NSCLC patients who harbor mutations in exons 19,
20, and 21 can still benefit from TKI, with superior
PFS to that in patients without any of these mutations
[76]. Therefore, TKI is still indicated in patients with
activating EGFR mutations on exons 19, and 21 with
or without T790M identified while additional treat-
ment should be added to overcome resistance due to
T790M. Resistance due to T790M can potentially over-
come by second generation irreversible EGFR TKIs,
which appear to be well tolerated in early clinical stud-
ies [5]. Although did not demonstrated an overall sur-
vival benefit, Afatinib, an irreversible EGFR, Her-2,
and ErbB4 blocker has led to significant PFS inpatients who progressed after a 12 week course of Gefi-
tinib or Erlotinib when compared to placebo in a phase
2b/3 trial [77]. This agent has been shown to be highly ef-
fective in adenocarcinoma harboring activating mutations
on exon 19 and 21 when compared with Cisplatin and
Pemetrexed (CP) approximately doubling the response
rate and PFS achieved with CP, which makes first line
treatment of choice in this cohort of patients [78].
Increased signaling through the PI3K pathway through
MET-trigger ErbB3 signaling in TKI-resistant NSCLC
cells overexpressing MET oncogene has been shown to
be a classic example of acquired resistance through
bypassing the EGFR, which can be overcome through
dual EGFR and MET inhibition [74]. This strategy has
been shown to be effective in pre-clinical studies. As
shown by Nakagawa et al., WZ4002, a mutant EGFR-
TKI, and E7050, a mutant selective dual inhibitor of Met
and VEGFR-2, were able to inhibit tumor growth in
Erlotinib resistant NSCLC cells in vitro and in vivo when
given together with successful inhibition of the EGFR,
Met, and their downstream PI3K-AKT pathway [79].
The combination of 2nd generation TKIs and MET inhi-
bitors with radiotherapy and/or chemotherapy still need
to be further investigated in future studies. In addition
to MET signaling stimulated PI3K signaling, BRAF mu-
tation in the RAS-RAF-MEK-MAPK pathway, and loss
of PTEN expression may also lead to acquired resistance
to an EGFR TKI [80,81].
As a another potential predictive biomarker for a lack
of response to EGFR TKIs in NSCLC, KRAS mutation
was only shown to be associated with treatment out-
come in selected studies [38,41]. It is observed in ap-
proximately 30% of adenocarcinomas [82]. Its mutated
form often leads to a gain of function in its downstream
signaling pathway, in particular, the Raf-MEK-ERK path-
way. This subsequently increases MAPK signaling and
tumor cell proliferation. In addition, the mutated KRAS
also leads to increased TGF-α expression, which further
stimulates the EGFR [82]. Although not consistently
demonstrated in major randomized phase III studies,
KRAS mutations was found to be significantly associated
with an absence of response to TKIs in NSCLC in a
meta-analysis of 17 studies [83]. The role of KRAS mu-
tation in major studies evaluating the efficacy of Cetuxi-
mab has not been clearly shown. Thus, the role of KRAS
mutation as a predictive biomarker for poor response to
EGFR inhibition needs to be further elucidated.
Due to differences of the EGFR inhibition mechanism
by the mAb, which can generate antibody dependent cel-
lular cytotoxicity; and TKIs ability to inhibit multiple types
of ErbB receptors, the role of dual blockade should be
explored further in the clinical as they have been shown to
increase the potency of EGFR inhibition in vitro and
in vivo [1,84]. Targeting downstream signaling pathways
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http://www.biomarkerres.org/content/1/1/2to the EGFR directly can also be a potential approach of
augmenting the antitumor activity of radiotherapy and
chemotherapy with EGFR inhibitors [85,86]. At last, sim-
ultaneously blocking the EGFR, its downstream signaling
pathway, such as the PI3K pathway, and parallel signaling
pathways alone, or combined with chemotherapy and
radiotherapy, may lead to maximal antitumor activity and
warrants further investigation in the future.Competing interests
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